Opthea Corp (OPT): תחזית צמיחת רווח נקי למניה לשנה הבאה

Opthea Limited expects the completion of final sozinibercept tests for the treatment of macular degeneration, which could lead to FDA approval. Patent protection for this unique therapy will ensure high market value for the company's products. The projected change in earnings per share for the coming year visualizes these expectations, where 92.90 represents the current level of the metric. The strategy is anchored by strong medical leadership that enjoys the trust of institutional investors.

For the biopharmaceutical company Opthea Limited (OPT), which is developing the unique VEGF-C/D inhibitor sozinibercept, this indicator reflects the consensus forecast for changes in earnings per share, determining the market value of future successes in AMD therapy. By analyzing the expected annual EPS growth rate for the coming year, an investor assesses the speed of analyst revision, which allows for the timely identification of asset overbought conditions or a fundamental trend reversal.